Skip to main content
OpenTrials
Completed

NCT Number: NCT06640036

FILIP: Fat Intake, Inflammation and LIPids

Low-grade inflammation is involved in the pathogenesis of type 2 diabetes and cardiovascular disease. Increasing evidence suggests that dietary intake may be involved in the inflammatory process. How nutritional composition of the diet affects the inflammatory response is however not well understood.

The aim of this project is to study if intake of three different fat sources induce different effects on inflammation markers, blood lipids, blood glucose and the microbiota.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cardiometabolic Risk Factors Inflammation Microbiota Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Gothenburg

Gothenburg, 40530, Sweden

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18-60
  • Willing to eat the study diet

Exclusion criteria

  • malabsorption-related condition
  • contraindications to consume a high fat diet
  • intolerance to any foods used in the study (e.g. cow's milk, egg, gluten)
  • established cardiovascular disease, diabetes or cancer
  • current use of medication known to affect lipid metabolism (e.g. statins) or inflammation (e.g. NSAID, glucocorticoids).
  • hemoglobin <100 g/L
  • ongoing pregnancy or lactation

Treatment and study plan

Rapeseed oil

Other

During 1 week, 46 % of total energy intake will come from rapeseed oil, using pre-prepared and blinded meals.

Butter

Other

During 1 week, 46 % of total energy intake will come from butter, using pre-prepared and blinded meals.

Coconut oil

Other

During 1 week, 46 % of total energy intake will come from coconut oil, using pre-prepared and blinded meals.

Primary outcomes

  1. Total cholesterol

    Time frame: Baseline and 1 week

  2. hs-CRP

    Time frame: Baseline and 1 week

    High sensitivity C-reactive Protein

Secondary outcomes

  1. Inflammation markers

    Time frame: Baseline and 1 week

    Eg. GlycA, IL6, TNF-a

  2. Blood lipid propfile

    Time frame: Baseline and 1 week

    Blood lipids and their subfractions, lipoproteins, apolipoproteins

  3. Glucose

    Time frame: Continuous during 1 week

    Glucose, measured by continuous blood glucose monitoring

  4. Microbiota

    Time frame: Baseline and 1 week

    Change in gut microbial composition and diversity (alpha- and beta).

Sponsors and collaborators

Lead sponsor

Göteborg University

Other

Collaborators

  • Chalmers University of Technology

Registry information

Acronym: FILIP

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Oct 15, 2024
Registry last updated
Feb 4, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.